Active · per the CBE, 16 November 2026

ComPro Pharma

BE0746429351

Rechtspersoon Private limited company 1 establishment

ComPro Pharma is a research organisation in Sprimont. Private Limited, started on 21 April 2020, 1 establishment.

Rue d'Ogné 36, 4140 Sprimont

Behind the company: FABIENNE WIJZEN.

Active for

6 year, 6 months

Financials

Financial year 2025

ComPro Pharma from Sprimont, company number BE0746429351, closed financial year 2025 with a result of € 54,298 after tax. For that financial year ComPro Pharma recorded a gross margin of € 77,795 and equity of € 9,170. Compared with financial year 2024, the result moved from € 56,892 to € 54,298. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 28, 2026.

What it is worth Growing

€ 9,170

▲ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 54,298

▼ 5% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 29,894

▼ 41% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 54,000 paid out

99 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 6,896

▼ 47% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 816

▲ € 813 vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1,139

▼ 43% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 11,754

▼ 27% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year
2022202320242025Change 2024 → 2025
Revenue € 145,500 € 160,650 - -
Gross margin € 57,173 € 72,664 € 75,112 € 77,795 ▲ 4%
Profit after taxes € 44,002 € 56,010 € 56,892 € 54,298 ▼ 5%
Equity € 130,971 € 6,980 € 8,872 € 9,170 ▲ 3%
Total debts € 33,000 € 86,367 € 73,161 € 67,709 ▼ 7%
Cash € 149,451 € 77,293 € 50,853 € 29,894 ▼ 41%
Retained profit € 126,971 € 2,980 € 4,872 € 5,170 ▲ 6%
Dividend € 0 € 180,000 € 55,000 € 54,000 ▼ 2%
Bank debt € 88 € 3 € 3 € 816 ▲ € 813
Balance sheet total € 163,971 € 93,347 € 82,033 € 76,879 ▼ 6%

By gross margin, ComPro Pharma ranks 32nd of 73 companies with main activity “Speur- en ontwikkelingswerk op biotechnologisch gebied” in the province of Liège that publish figures (fiscal year 2025).

Key figures of ComPro Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ComPro Pharma?

What happened at ComPro Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: profit of € 54,298 (▼ 5% vs 2024). Source: NBB ↗
  • Incorporation, published in the Gazette. Source: Staatsblad ↗
  • New establishment in Sprimont. KBO
  • FABIENNE WIJZEN became a director. NBB

In short

From € 44,002 profit in 2022 to € 54,298 profit in 2025.

Paid € 59,199 in corporate taxes since 2022.

Best year ever: 2024, with € 56,892 profit.

Paid out € 289,000 in dividends to the owners in total.

Management

FABIENNE WIJZEN
ComPro Pharma

Behind ComPro Pharma is FABIENNE WIJZEN.

Directors

According to the 2025 annual accounts

FABIENNE WIJZEN

Director

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Rue d'Ogné 36

4140 Sprimont

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Similar companies in the province of Liège

Same main activity (Speur- en ontwikkelingswerk op biotechnologisch gebied), 94 active companies in the province of Liège, largest first.

TELIX INNOVATIONS

€ 243.8 million revenue · 2025 · Herstal

KANEKA EUROGENTEC

€ 49.4 million revenue · 2026 · Seraing

DIAGENODE

€ 11.9 million revenue · 2025 · Seraing

LaCAR MDx technologies

€ 8.1 million revenue · 2025 · Liège

MDxHealth

€ 4.2 million revenue · 2025 · Herstal

OSIVAX Belgique

€ 3.9 million gross margin · 2025 · Liège

Shareholders according to the Official Gazette deeds

Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.

Incorporation

Source: Deed ↗
  • WIJZEN Fabienne Marie Marguerite(fondateur) 75%
  • DELAUNOY Jean-Marc Emile Joseph(simple souscripteur) 25%

Details

Company number
0746.429.351
VAT number
BE 0746.429.351
Registered office
Rue d'Ogné 36, 4140 Sprimont
Names & denominations
ComPro Pharma
Enterprise type
Rechtspersoon
Legal form
Private limited company
Legal situation
Normale toestand
Start date
21 April 2020
Peppol
Active · Active since 7 Nov 2025
Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Frequently asked questions

What does ComPro Pharma do?
ComPro Pharma is a research organisation in Sprimont. Private Limited, started on 21 April 2020, 1 establishment.
What is the address of ComPro Pharma?
The registered office of ComPro Pharma is located at Rue d'Ogné 36, 4140 Sprimont.
Is ComPro Pharma still active?
Yes. According to the CBE (16 November 2026) ComPro Pharma is active, legal situation “Normale toestand”, started on 21 April 2020.
Is ComPro Pharma registered on Peppol?
Yes, ComPro Pharma is registered on the Peppol network with ID 0208:0746429351.
What is the enterprise number of ComPro Pharma?
The enterprise number of ComPro Pharma is BE0746429351.
When was ComPro Pharma founded?
ComPro Pharma was founded on 21 April 2020.